Armored Likho BusySnake Stealer, a Python-based infostealer first disclosed by Kaspersky, is actively targeting government ...

The former majority owner of TikTok has quietly continued to court filmmakers, independent artists and executives who are ...

See how LLMs, APIs and scripts cut busywork, uncover AI search signals and help teams move faster without ditching core SEO ...

Addressing the pervasive challenges within the software development lifecycle (SDLC), such as poorly defined requirements, ...

On June 24, 2026, Microsoft’s Digital Crimes Unit (DCU) facilitated the takedown, suspension, and blocking of domains that ...

Abstract: Large language models (LLMs) are increasingly being used in various domains, including chip design. Recent works have demonstrated the effectiveness of LLMs in EDA tool script generation.

Discover the top 12 tools in 2026, from Cursor to Copilot, to speed up daily dev workflows and build apps faster!

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...

Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. The Flagship-founded biotech has yet to set out how many ...